Note

Fairfax Completes US$1 Billion Senior Notes Offering

Retrieved on: 
Friday, March 22, 2024
Failure, Risk management, Asbestos, EDGAR, Regulation, Sale, IAS 12, Insurance, TSX, Investment, Note, Annual report, Fairfax Financial, FFH, IAS, Government, Security (finance)

TORONTO, March 22, 2024 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) has completed its previously announced offering of US$1,000,000,000 in aggregate principal amount of 6.350% senior notes due 2054 (the “Notes”).

Key Points: 
  • TORONTO, March 22, 2024 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) has completed its previously announced offering of US$1,000,000,000 in aggregate principal amount of 6.350% senior notes due 2054 (the “Notes”).
  • In connection with the closing of the offering, Fairfax entered into a customary registration rights agreement.
  • Fairfax intends to use the net proceeds of this offering for general corporate purposes.
  • Such forward-looking statements may include, among other things, the intended use of the net proceeds from the offering of the Notes.

Bombardier Announces Launch of its New Issuance of Senior Notes due 2031

Retrieved on: 
Friday, March 22, 2024
Bombardier Inc., Sale, Regulation, Prospectus, Tender offer, Note, Debt-to-GDP ratio, Bombardier, Hand, Person

MONTRÉAL, March 22, 2024 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has launched an offering of US$500 million aggregate principal amount of new Senior Notes due 2031 (the “New Notes”).

Key Points: 
  • MONTRÉAL, March 22, 2024 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has launched an offering of US$500 million aggregate principal amount of new Senior Notes due 2031 (the “New Notes”).
  • This announcement does not constitute an offer to purchase or the solicitation of an offer to sell the New Notes, the 2026 Notes or the 2027 Notes.
  • This announcement does not constitute a redemption notice in respect of any 2027 Notes or any other notes.
  • Any redemption of the 2027 Notes or any other notes will be made pursuant to a notice of redemption under the indentures governing such notes.

Ryman Hospitality Properties, Inc. Announces Upsizing and Pricing of $1.0 Billion of Senior Notes Due 2032

Retrieved on: 
Thursday, March 21, 2024
Convention center, Issuer, Sale, Regulation, Note, Wells Fargo, National Association, Ryman Hospitality Properties, Person, Security (finance)

The aggregate principal amount of the Notes to be issued in the offering was increased to $1.0 billion from the previously announced $800.0 million.

Key Points: 
  • The aggregate principal amount of the Notes to be issued in the offering was increased to $1.0 billion from the previously announced $800.0 million.
  • The Notes will be senior unsecured obligations of the Issuers and guaranteed by the Company and its subsidiaries that guarantee its existing credit facility, 4.750% senior unsecured notes due 2027, 7.250% senior unsecured notes due 2028 and 4.500% senior unsecured notes due 2029.
  • Subject to customary closing conditions, the Issuers expect the private placement of the Notes to close on March 28, 2024.
  • There can be no assurance that the offering of the notes will be consummated.

Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities – Hagens Berman

Retrieved on: 
Thursday, March 21, 2024
SAN, Bank statement, CDMO, Hagens Berman, Note, Sale, Person, Cryptocurrency

12, 2024 after the CDMO announced the need to restate its financial performance over several quarters in 2022 and 2023.

Key Points: 
  • 12, 2024 after the CDMO announced the need to restate its financial performance over several quarters in 2022 and 2023.
  • The company blamed the misreporting on its misclassification of certain notes as long term liabilities and its failures to record additional interest expenses payable to note holders.
  • The debt in question is $143.8 million of 1.250% exchangeable senior notes due 2026 (“2026 Notes”) that Avid privately placed with qualified institutional investors in Mar.
  • In addition, the indenture governing the 2026 Notes required Avid to remove the legend by Mar.

Ryman Hospitality Properties, Inc. Announces Proposed $800 Million Senior Notes Offering

Retrieved on: 
Thursday, March 21, 2024
Convention center, Issuer, Sale, Regulation, Note, Wells Fargo, National Association, Ryman Hospitality Properties, Person, Security (finance)

NASHVILLE, Tenn., March 21, 2024 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”) announced today that its subsidiaries, RHP Hotel Properties, LP (the “Operating Partnership”) and RHP Finance Corporation (together, with the Operating Partnership, the “Issuers”), intend to offer, in a private placement, subject to market and other conditions, up to $800 million aggregate principal amount of senior notes due 2032 (the “Notes”).

Key Points: 
  • NASHVILLE, Tenn., March 21, 2024 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”) announced today that its subsidiaries, RHP Hotel Properties, LP (the “Operating Partnership”) and RHP Finance Corporation (together, with the Operating Partnership, the “Issuers”), intend to offer, in a private placement, subject to market and other conditions, up to $800 million aggregate principal amount of senior notes due 2032 (the “Notes”).
  • The Notes will be senior unsecured obligations of the Issuers and guaranteed by the Company and its subsidiaries that guarantee its existing credit facility, 4.750% senior unsecured notes due 2027, 7.250% senior unsecured notes due 2028 and 4.500% senior unsecured notes due 2029.
  • There can be no assurance that the offering of the notes will be consummated.
  • The Notes have not been registered under the Securities Act and will not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

Fairfax Announces Pricing of Senior Notes Offering

Retrieved on: 
Tuesday, March 19, 2024
Failure, Risk management, Asbestos, EDGAR, Regulation, Sale, IAS 12, United, Insurance, TSX, Investment, Note, Annual report, Fairfax Financial, FFH, IAS, Government, Security (finance)

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has priced a private offering of US$1,000,000,000 of senior notes due 2054 (the “Notes”) at an issue price of 99.734%.

Key Points: 
  • TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has priced a private offering of US$1,000,000,000 of senior notes due 2054 (the “Notes”) at an issue price of 99.734%.
  • The Notes will be unsecured obligations of Fairfax and will pay a fixed rate of interest of 6.350% per annum.
  • Fairfax also intends to enter into a registration rights agreement in connection with the offering.
  • Such forward-looking statements may include, among other things, the intended use of net proceeds from the offering of the Notes and the anticipated completion of the offering of the Notes.

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Retrieved on: 
Tuesday, March 19, 2024
AEON, Private placement, Private, LTD, FPA, Sale, Migraine, Note, Alembic Pharmaceuticals, AB toxin, Food, FDA, Pharmaceutical industry

IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE AMEX: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced it has entered definitive agreements relating to a private placement (the "Private Placement") of $15 million (the “Investment Amount”) aggregate principal amount of senior secured convertible notes (the "Notes") with Daewoong Pharmaceutical Co., LTD. Proceeds from the Private Placement will be paid in a first installment of $5 million and a second installment of $10 million, in each case subject to the closing conditions set forth in the agreements. The Company expects the first installment to close before the end of March 2024 and the second to close in April 2024. Proceeds from the Private Placement will be used to support the late-stage clinical development of ABP-450 and for general working capital purposes. Upon funding of the second installment of the Investment Amount, the Company will appoint one designee of Daewoong to the AEON Board of Directors, subject to a customary due diligence process by AEON. The Daewoong designee must be a member of Daewoong’s senior management team.

Key Points: 
  • Proceeds from the Private Placement will be paid in a first installment of $5 million and a second installment of $10 million, in each case subject to the closing conditions set forth in the agreements.
  • The Company expects the first installment to close before the end of March 2024 and the second to close in April 2024.
  • Proceeds from the Private Placement will be used to support the late-stage clinical development of ABP-450 and for general working capital purposes.
  • Concurrent with the execution of the agreements for the Private Placement, the Company terminated its forward purchase agreements (each an “FPA” and the counterparties thereto, together, the “FPA Providers”).

Zoom Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024

Retrieved on: 
Tuesday, March 19, 2024
Editorial, Clip, Culture, Organization, MIC, Zoom Video Communications, SAN, AI, Hope, ITunes, Zoom, Note, Most, Meeting, Medical device

SAN JOSE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM), has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024.

Key Points: 
  • SAN JOSE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM), has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024.
  • Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions.
  • The World's Most Innovative Companies stands as Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year.
  • This event celebrates the Most Innovative Companies honorees and provides an inside look at cutting-edge business trends and what it takes to innovate in 2024.

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation into Avid Bioservices, Inc. (NASDAQ: CDMO) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Retrieved on: 
Monday, March 18, 2024
Failure, CDMO, Biotechnology, Acceleration, News, LLP, Bank statement, Note, Debt-to-GDP ratio, Security (finance)

If you have information that could assist in the Avid Bioservices Investigation or if you are an Avid Bioservices investor who suffered a loss and would like to learn more, you can provide your information HERE .

Key Points: 
  • If you have information that could assist in the Avid Bioservices Investigation or if you are an Avid Bioservices investor who suffered a loss and would like to learn more, you can provide your information HERE .
  • THE COMPANY: Avid Bioservices is a contract development and manufacturing organization based in Tustin, California.
  • They provide process development and manufacturing services to the biotechnology and biopharmaceutical industries, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support.
  • On this news, the price of Avid Bioservices stock fell over 28% in intraday trading on March 7, 2024.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Retrieved on: 
Monday, March 18, 2024
Department of Defence, Food and Drug Administration, Burn, Learning, Patient, BVA, Sale, Nature, Statistics, Investment, Note, LVAD, ICU, Duke, Form, Blood volume, NIH, Heart failure, Length of stay, American College, Operation, Hand, Health, Food, Sepsis, Acceleration, Letter, Proxy, Knowledge, Research, Hospital, Acquisition, CLIA, Clinical study design, Family, FDA, Consultant, Annual general meeting, Diagnosis, RCT, Financial statement, Growth, Syncope, Mortality, National Institutes of Health, Nursing care plan, Bangladesh Technical Education Board, Net, Government, Physician, Medicine, Pharmaceutical industry

We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expansion means for both the company and the tens of millions of patients whose care we are eager to significantly improve. In every area 2023 and the strong start of 2024 has shown substantial progress for the company -- in revenue growth, new customer acquisitions, increasing utilization of our products by existing customers, next generation systems completed and under Food and Drug Administration (FDA) review, positive clinical studies, new patents granted and pending, successful National Institutes of Health (NIH) grant awards, Department of Defense (DoD) contracts awarded, and further research and development for groundbreaking products set to launch in subsequent fiscal years. I will detail below more in these areas but first wish to review why our company’s mission to commercialize the products that enable optimal patient care is so vital.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
  • Many of these markers are costly, some are invasive, and none are accurate – in contrast to Daxor’s proven 98% accurate system.
  • Care teams cannot effectively treat what they do not correctly diagnose, so our rapid accurate diagnostic test is a game-changer.
  • Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012.